Distribution of NQO1 genotypes in pediatric patients with MLL(+) and MLL(−) leukemias
| . | High NQO1 activity CC genotype (%) . | Low NQO1 activity CT genotype (%) . | Null NQO1 activity TT genotype (%) . | Low/null NQO1 activity CT/TT gneotype (%) . | OR (95% CI, range)* (vs MLL(−) de novo B-lineage ALL) . |
|---|---|---|---|---|---|
| MLL(+) de novo | 15 (38.5) | 22 (56.4) | 2 (5.1) | 24 (61.5) | 2.47 (1.08-5.68)P = .033 |
| MLL(+) therapy-related | 13 (72.2) | 5 (27.8) | 0 | 5 (27.8) | 0.59 (0.19-1.85)P = .378 |
| MLL(−) de novo B-lineage ALL | 34 (60.7) | 18 (32.2) | 4 (7.1) | 22 (39.3) | Ref |
| Expected† | (61) | (34) | (5) | (39) | Ref |
| . | High NQO1 activity CC genotype (%) . | Low NQO1 activity CT genotype (%) . | Null NQO1 activity TT genotype (%) . | Low/null NQO1 activity CT/TT gneotype (%) . | OR (95% CI, range)* (vs MLL(−) de novo B-lineage ALL) . |
|---|---|---|---|---|---|
| MLL(+) de novo | 15 (38.5) | 22 (56.4) | 2 (5.1) | 24 (61.5) | 2.47 (1.08-5.68)P = .033 |
| MLL(+) therapy-related | 13 (72.2) | 5 (27.8) | 0 | 5 (27.8) | 0.59 (0.19-1.85)P = .378 |
| MLL(−) de novo B-lineage ALL | 34 (60.7) | 18 (32.2) | 4 (7.1) | 22 (39.3) | Ref |
| Expected† | (61) | (34) | (5) | (39) | Ref |
Ref indicates reference group.
OR generated from 2 × 2 table using chi-square test comparing CC versus CT/TT.
Expected in the MLL(+) de novo group on the basis of ethnicity using the following allele frequencies: white, 0.21; African American, 0.23; Hispanic, 0.39; and Asian, 0.45. Expected allele frequency would therefore be 0.22 based on the ethnic mix shown in Table 1.